RYBELSUS

Peak

oral semaglutide

NDAORALTABLETPriority Review
Approved
Sep 2019
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20

Mechanism of Action

Glucagon-like Peptide-1 (GLP-1) Agonists

Pharmacologic Class:

GLP-1 Receptor Agonist

Clinical Trials (5)

NCT05714683N/ANot Yet Recruiting

Regulatory Post Marketing Surveillance (rPMS) Study of Rybelsus (Oral Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea

Started Dec 2025
600 enrolled
Diabetes Mellitus, Type 2
NCT07271251Phase 3Recruiting

A Research Study to See if Two Different Formulations of Oral Semaglutide Are Equally Safe and Effective in Reducing the Blood Sugar Level in Japanese People With Type 2 Diabetes

Started Dec 2025
264 enrolled
Type 2 Diabetes
NCT06269120N/ARecruiting

SEMA-CardioDiab HUNGARY: A Research Study to Understand the Effects of Oral Semaglutide on Blood Sugar Levels, Weight, and Cardiovascular Risk in People With Type 2 Diabetes Patients in Hungary

Started Sep 2024
470 enrolled
Type 2 Diabetes
NCT06507475N/ACompleted

Real World Effectiveness of Oral Semaglutide in Thailand Participants With Type 2 Diabetes

Started Sep 2024
209 enrolled
Diabetes Mellitus, Type 2
NCT05784402Phase 1Completed

A Research Study to Compare How Much Semaglutide is Found in the Blood With Different Tablets of Oral Semaglutide in Healthy Participants

Started Mar 2023
264 enrolled
Healthy Participants

Loss of Exclusivity

LOE Date
Feb 1, 2039
157 months away
Patent Expiry
Feb 1, 2039
Exclusivity Expiry
Oct 17, 2028

Patent Records (5)

Patent #ExpiryTypeUse Code
8536122
Mar 20, 2026
SubstanceProduct
U-2628
8129343
Dec 5, 2031
SubstanceProduct
U-2628
11382957
Dec 16, 2031
SubstanceProduct
10086047
Dec 16, 2031
Product
10960052
Dec 16, 2031
Product